Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Apoio eletrônico à decisão multi-hospitalar para lesão renal aguda associada a medicamentos (MEnD-AKI)

16 de outubro de 2026 atualizado por: Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM, University of Pittsburgh

Apoio eletrônico à decisão multi-hospitalar para lesão renal aguda associada a medicamentos (MEnD-AKI)

This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.

The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.

Tipo de estudo

Intervencional

Inscrição (Real)

698

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Pennsylvania
      • Altoona, Pennsylvania, Estados Unidos, 16601
        • UPMC Altoona
      • Farrell, Pennsylvania, Estados Unidos, 16121
        • UPMC Horizon
      • McKeesport, Pennsylvania, Estados Unidos, 15132
        • UPMC McKeesport
      • New Castle, Pennsylvania, Estados Unidos, 16105
        • UPMC Jameson
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Shadyside
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • UPMC Magee
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • UPMC Presbyterian/Montefiore
      • Williamsport, Pennsylvania, Estados Unidos, 17701
        • UPMC Williamsport

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Physician-subject Inclusion

  • Physicians employed at UPMC hospital systems
  • Attending physicians of record who care for patients across multiple units outside ICU/ED
  • Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI

Physician-subject Exclusion

  • Physicians of record who only care for ICU or ED patients
  • Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients
  • Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.)

Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.

Patient-subject Inclusion

  • System alert identifying risk for AKI
  • Patient has attending physician who is participating in the randomized clusters
  • After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91

Patient-subject Exclusion

• Patients with end stage renal disease on admission, baseline eGFR <15, comfort measures only, or died before the intervention could be delivered

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Protocolized stage-based intervention

The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval.

Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.

The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.

Comparador Ativo: Usual Care

A Cerner EMR-based AKI passive alert which is standard of care at UPMC.

Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
Prazo: up to 30 days

Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so ~ 3000 patients were included for the per protocol analysis to be impactful.

up to 30 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
Prazo: up to 30 days

Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first.

Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first.

Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first.

The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert.

up to 30 days
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
Prazo: up to 30 days

AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians.

up to 30 days
Nephrotoxic Burden
Prazo: up to 30 days

Drug.days* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients.

*Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day.

up to 30 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Azra Bihorac, MD, MS, University of Florida
  • Investigador principal: Sandra L Kane-Gill, PharmD, MS, University of Pittsburgh

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de fevereiro de 2024

Conclusão Primária (Real)

15 de julho de 2025

Conclusão do estudo (Real)

15 de julho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

8 de fevereiro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de fevereiro de 2024

Primeira postagem (Real)

20 de fevereiro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • STUDY20120008
  • R01DK121730 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .